Reunion Neuroscience Company Profile, Contacts & Intelligence
Reunion Neuroscience Overview
Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions. In August of 2023, Reunion Neuroscience became a private company and in May 2024, the Company completed a Series A financing co-led by MPM BioImpact and Novo Holdings. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression and adjustment disorder, as well as in additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care. The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. In a Phase 1 clinical trial, RE104 produced a psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe postpartum depression (PPD) patients. Reunion plans to initiate the REKINDLE Phase 2 clinical trial, a randomized, double-blind, parallel-group, dose-controlled trial in adjustment disorder (AjD) in cancer and other medical illnesses. The RECONNECT Phase 2 clinical trial (NCT06342310), a multicenter, randomized, double-blind, active dose-controlled clinical trial, is evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. To learn more about the study and eligibility for enrollment, please visit www.ppdreconnectstudy.com.
- Website
- www.reunionneuro.com
- Industry
- Biotechnology
Reunion Neuroscience Contact Intelligence
See which contact channels and departments are represented in the visible AeroLeads data.
Reunion Neuroscience People & Org Chart Preview
Sample people records show job titles and whether email or phone data is available without exposing raw contact details.
Reunion Neuroscience Workforce Composition
Seniority breakdown across 4 visible profiles.
Compare Similar Companies to Reunion Neuroscience
Explore companies in related markets and compare their industry and employee estimates.
| Company | Industry / match | Employee estimate | Page |
|---|---|---|---|
| MindMed | Biotechnology Research | 115 | View company |
| Lykos Therapeutics | Biotechnology Research | 90 | View company |
| Cybin Inc | Biotechnology Research | 80 | View company |
| atai Life Sciences | Biotechnology Research | 76 | View company |
| Beckley Psytech | Pharmaceutical Manufacturing | 66 | View company |
| MPM BioImpact | Venture Capital And Private Equity Principals | 61 | View company |
| Seaport Therapeutics | Biotechnology Research | 55 | View company |
| Latus Bio | Biotechnology Research | 33 | View company |
| Field Trip Health (Now Stella Mental Health) | Wellness And Fitness Services | 31 | View company |
| Delphia Therapeutics | Biotechnology Research | 29 | View company |